The Federal Commission for the Protection against Sanitary Risks (Cofepris) of Mexico granted a sanitary license to the company Medicinas y Medicamentos Nacionales, a subsidiary of the company Genome Labto operate its manufacturing lines for over-the-counter medical products.
“As a result, the OTC (over-the-counter medicine) plant operation license application phase has been concluded. All manufacturing lines can now manufacture a wide range of pharmaceuticals”, expressed Genomma Lab in a statement.
This license, according to Rodrigo Herrera Aspra, president of the pharmaceutical company’s board, seeks to position the company as a leader in pharmaceutical and personal care products throughout the Americas.
Meanwhile, Marco Sparvieri, general director of the company, assured that this license will help promote optimal agility and speed in fundamental processes such as manufacturing, product innovation and an increase in service capacity.
In 2019, Cofepris granted the pharmaceutical company the health license for its new manufacturing plant, while in 2021 the company received the certificate of good manufacturing practices for its pharmaceutical products in solid and semi-solid format.
Genomma Lab’s manufacturing plant is in Toluca, State of Mexico, where it has more than 70,000 square meters of construction, from where it exports to the 18 international markets in which it has a presence.
This type of licenses occurs in the midst of the crisis due to the shortage of medicines in the health sector that worsened in 2019 due to budget cuts and changes in the purchase of medicines by the Government of Andrés Manuel López Obrador, who assumed the Presidency on December 1, 2018.
Besides, in 2020 the situation was complicated by the impact of the covid-19 pandemic, which unleashed protests and a political crisis for the Government.
MORE NEWS:
EFE International news agency based in Madrid and present in more than 110 countries.